Gyala Therapeutics initiates phase I/IIa trial of a CAR-T cell therapy for acute leukaemias with limited treatment: Barcelona, Spain Wednesday, February 11, 2026, 18:00 Hrs [IST] ...
Capturing the immunotherapy opportunity in myeloid blood cancers In the fourth quarter of 2025, Mendus presented continued positive long-term survival data of the ADVANCE II trial in acute myeloid leu ...
Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody ...
Regulatory alignment from the FDA and MD Anderson IRB supports resumption of enrollment in a U.S./European proof-of-concept ...
A comprehensive single-cell atlas of AML uncovers regulatory networks and age-dependent molecular differences to advance the understanding of disease mechanisms and enable subtype-specific therapeutic ...
In this article, we assess the risk of developing haematopoietic cancers post-modRNA vaccination based on current scientific literature and explore ...
A mum who blamed her lower back pain on sleeping on an old mattress was devastated when she was diagnosed with an aggressive leukaemia. Gabrielle Altoft says she started experiencing 'horrendous' ...
Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite ...
Circulating tumor DNA may be an effective biomarker for stratifying patients with small cell lung cancer who would benefit from more stringent follow-ups and clinical trial participation.Patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results